Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROCEPT BioRobotics Corp
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,791 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 8,791 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08 | Direct | 5,853 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853 F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Shockwave Medical, Inc.
Report date February 05, 2024 · Filed February 07, 2024
Section 16 reporting ended · disclosed 2024-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,005 |
Ending reported balance
After 2024-02-05 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-02-05 · Tax withholding · Disposed 2,208 · Balance 25,524 Row 2 · 2024-02-05 · Tax withholding · Disposed 1,077 · Balance 24,447 Row 3 · 2024-02-05 · Tax withholding · Disposed 213 · Balance 24,234 Row 4 · 2024-02-05 · Sale · Disposed 300 · Balance 23,934 F1: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F2: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $229.12 to $229.34. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Row 5 · 2024-02-05 · Sale · Disposed 1,703 · Balance 22,231 F1: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F3: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $230.67 to $231.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Row 6 · 2024-02-05 · Sale · Disposed 1,226 · Balance 21,005 F1: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F4: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $231.70 to $232.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Filing footnotes · ownership attribution and instrument terms
F1: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023.
F2: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $229.12 to $229.34. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F3: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $230.67 to $231.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $231.70 to $232.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 20:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 5,853 | $0.00 Strike: $28.78 | $0.00 |
DisclosureSEC source: 0001628280-26-042252 · wk-form4_1781123684.xml · derivative · entry 2 PUCKETT DAN · CIK 0001602773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,853 Underlying: Common Stock · 5,853 shares Expires 2036-06-08 F2 · derivative.exercise_date: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 20:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 3,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042252 · wk-form4_1781123684.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,791 F1 · kind: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:39 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 8,897 | $0.00 Strike: $25.35 | $0.00 |
DisclosureSEC source: 0001628280-26-016149 · wk-form4_1773092380.xml · derivative · entry 2 PUCKETT DAN · CIK 0001602773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,897 Underlying: Common Stock · 8,897 shares Expires 2036-03-04 F2 · derivative.exercise_date: This Stock Option was granted on March 5, 2026, and one-third of the shares subject to the Stock Option shall vest on March 5, 2027, with one-third of the remaining shares subject to the Stock Option vesting annually on each of the second and third anniversary thereof, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:39 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 5,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-016149 · wk-form4_1773092380.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,476 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on March 5, 2027, with one-third of the remaining RSUs vesting annually on each of the second and third anniversary thereof, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:10 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,226 | $231.84 | $284,235.84 |
DisclosureSEC source: 0001642545-24-000034 · wk-form4_1707268208.xml · nonDerivative · entry 6 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,005 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $231.70 to $232.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:10 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,703 | $230.99 | $393,375.97 |
DisclosureSEC source: 0001642545-24-000034 · wk-form4_1707268208.xml · nonDerivative · entry 5 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,231 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $230.67 to $231.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:10 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 300 | $229.27 | $68,781.00 |
DisclosureSEC source: 0001642545-24-000034 · wk-form4_1707268208.xml · nonDerivative · entry 4 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,934 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $229.12 to $229.34. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:10 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 213 | $226.32 | $48,206.16 |
DisclosureSEC source: 0001642545-24-000034 · wk-form4_1707268208.xml · nonDerivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,234 Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:10 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 1,077 | $226.29 | $243,714.33 |
DisclosureSEC source: 0001642545-24-000034 · wk-form4_1707268208.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,447 Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:10 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 2,208 | $226.29 | $499,648.32 |
DisclosureSEC source: 0001642545-24-000034 · wk-form4_1707268208.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,524 Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 01:03 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 11 | $231.16 | $2,542.76 |
DisclosureSEC source: 0001642545-24-000023 · wk-form4_1706922205.xml · nonDerivative · entry 4 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,732 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 01:03 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,692 | $230.74 | $390,412.08 |
DisclosureSEC source: 0001642545-24-000023 · wk-form4_1706922205.xml · nonDerivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,743 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $230.16 to $231.14. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 01:03 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 613 | $229.24 | $140,524.12 |
DisclosureSEC source: 0001642545-24-000023 · wk-form4_1706922205.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,435 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $228.95 to $229.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 01:03 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,090 | $228.53 | $249,097.70 |
DisclosureSEC source: 0001642545-24-000023 · wk-form4_1706922205.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,048 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 09/08/2023. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $227.95 to $228.93. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 01:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 2,114 | $212.97 | $450,218.58 |
DisclosureSEC source: 0001642545-24-000010 · wk-form4_1705540896.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,138 Read SEC document |
| January 12, 2024 Filed Jan 18, 2024 01:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 5,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000010 · wk-form4_1705540896.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,252 F1 · shares: Represents the vesting and settlement of a performance-based restricted stock unit award granted on February 1, 2022, resulting from the achievement of certain performance criteria related to the compound annual growth rate of the Issuers revenue during the measurement period January 1, 2022 through December 31, 2023. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 01:03 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 200 | $173.88 | $34,776.00 |
DisclosureSEC source: 0001209191-23-058142 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,784 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/8/2023. F2 · price: All reported securities were sold at a price of $173.88. Read SEC document |
| November 02, 2023 Filed Nov 16, 2023 01:17 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 204 | $214.07 | $43,670.28 |
DisclosureSEC source: 0001209191-23-055438 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,984 F1 · price: All reported securities were sold at a price of $214.07. Read SEC document |
| August 03, 2023 Filed Aug 5, 2023 00:03 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 210 | $250.10 | $52,521.00 |
DisclosureSEC source: 0001209191-23-044690 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,188 Read SEC document |
| May 11, 2023 Filed May 13, 2023 00:19 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,050 | $291.95 | $598,497.50 |
DisclosureSEC source: 0001209191-23-029233 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,398 F1 · price: All reported securities were sold at a price of $291.95. Read SEC document |
| May 03, 2023 Filed May 6, 2023 00:13 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 210 | $280.76 | $58,959.60 |
DisclosureSEC source: 0001209191-23-027845 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,448 F1 · price: All reported securities were sold at a price of $280.76. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 00:06 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,002 | $264.67 | $265,199.34 |
DisclosureSEC source: 0001209191-23-024921 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,658 F2 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · price: All reported securities were sold at a price of $264.67. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 00:06 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 998 | $267.97 | $267,434.06 |
DisclosureSEC source: 0001209191-23-024921 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,660 F1 · price: All reported securities were sold at a price of $267.97. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 01:17 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-23-020686 · doc4.xml · derivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 01:17 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $200.74 | $220,814.00 |
DisclosureSEC source: 0001209191-23-020686 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,658 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $200.74. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 01:17 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,100 | $17.00 | $18,700.00 |
DisclosureSEC source: 0001209191-23-020686 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 3,653 | $191.69 | $700,243.57 |
DisclosureSEC source: 0001209191-23-012408 · doc4.xml · nonDerivative · entry 4 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,658 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012408 · doc4.xml · derivative · entry 5 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,180 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F4 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 3,847 | $192.86 | $741,932.42 |
DisclosureSEC source: 0001209191-23-012408 · doc4.xml · nonDerivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,311 F3 · price: All reported securities were sold at a price of $192.86. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $192.84 | $212,124.00 |
DisclosureSEC source: 0001209191-23-012408 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,158 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $192.84. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,100 | $17.00 | $18,700.00 |
DisclosureSEC source: 0001209191-23-012408 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 01:57 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 3,221 | $188.26 | $606,385.46 |
DisclosureSEC source: 0001209191-23-007200 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,231 F1 · price: All reported securities were sold at a price of $188.26. Read SEC document |
| February 02, 2023 Filed Feb 8, 2023 01:09 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,073 | $190.25 | $394,388.25 |
DisclosureSEC source: 0001209191-23-007698 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,158 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $190.25. Read SEC document |
| February 01, 2023 Filed Feb 4, 2023 01:57 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 6,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007200 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,452 Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 01:19 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004504 · doc4.xml · derivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,280 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 01:19 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $177.45 | $195,195.00 |
DisclosureSEC source: 0001209191-23-004504 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,938 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $177.45. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 01:19 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,100 | $17.00 | $18,700.00 |
DisclosureSEC source: 0001209191-23-004504 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 02:23 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062380 · doc4.xml · derivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,380 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 02:23 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $212.93 | $234,223.00 |
DisclosureSEC source: 0001209191-22-062380 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,938 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $212.93. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 02:23 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,100 | $17.00 | $18,700.00 |
DisclosureSEC source: 0001209191-22-062380 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058542 · doc4.xml · derivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,480 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $246.96 | $271,656.00 |
DisclosureSEC source: 0001209191-22-058542 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,938 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $246.96. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 01:08 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,100 | $17.00 | $18,700.00 |
DisclosureSEC source: 0001209191-22-058542 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| October 20, 2022 Filed Oct 22, 2022 00:30 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054344 · doc4.xml · derivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,580 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
| October 20, 2022 Filed Oct 22, 2022 00:30 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $268.35 | $295,185.00 |
DisclosureSEC source: 0001209191-22-054344 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,938 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $268.35. Read SEC document |
| October 20, 2022 Filed Oct 22, 2022 00:30 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,100 | $17.00 | $18,700.00 |
DisclosureSEC source: 0001209191-22-054344 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 00:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050958 · doc4.xml · derivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,680 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 00:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $291.33 | $320,463.00 |
DisclosureSEC source: 0001209191-22-050958 · doc4.xml · nonDerivative · entry 2 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,938 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F2 · price: All reported securities were sold at a price of $291.33. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 00:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,100 | $17.00 | $18,700.00 |
DisclosureSEC source: 0001209191-22-050958 · doc4.xml · nonDerivative · entry 1 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 00:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047276 · doc4.xml · derivative · entry 3 PUCKETT DAN · CIK 0001602773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,780 Underlying: Common Stock · 1,100 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/9/2022. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly from 03/06/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.